
Gene Therapy Stocks That Turn Science Into Sales: 7 Picks
A countdown of seven gene therapy stocks spans commercial treatments, gene-editing platforms, rare-disease specialists, and diversified pharmaceutical exposure.
Every article, report, and earnings note where RARE appears.

A countdown of seven gene therapy stocks spans commercial treatments, gene-editing platforms, rare-disease specialists, and diversified pharmaceutical exposure.

OHB Pediatrics Ltd. d/b/a Oak Hill Bio is going public through a merger with Research Alliance Corp III, the SPAC trading as RACC, with closing expected by year-end 2026. The setup is attractive if you want a Phase 3 rare-disease biotech with committed financing, but shareholders should watch dilution, clinical risk, and whether the market gives credit to a single-asset story.

Clinuvel Pharmaceuticals Limited American Depositary Shares are expected to list on NASDAQ on 2026-07-20, but the price range has not been disclosed. The setup looks more like an ADR listing upgrade than a classic new-money IPO, with an established profitable specialty pharma business behind it.
Generate an AI-powered research report — grades, price targets, financials, and chart analysis on demand.
Generate RARE ReportCancel anytime